respiratori
tract
surfac
protect
inhal
pathogen
secret
layer
mucu
rich
mucin
glycoprotein
disrupt
mucu
product
cardin
featur
chronic
respiratori
diseas
alter
affect
interact
mucin
pathogen
complex
poorli
understood
identifi
central
unexpect
role
major
airway
mucin
pathogenesi
virusinduc
exacerb
chronic
obstruct
pulmonari
diseas
copd
viru
induct
augment
copd
compar
healthi
subject
enhanc
frequent
exacerb
correl
inflamm
symptom
sever
secondari
bacteri
infect
exacerb
function
relat
inflamm
mice
attenu
rhinovirusinduc
airway
inflamm
whilst
exogen
glycoprotein
administr
augment
virusinduc
inflammatori
respons
bacteri
load
mechanist
rhinovirusinduc
inflamm
occur
releas
extracellular
adenosin
triphosph
atp
therapeut
suppress
virusinduc
releas
use
epiderm
growth
factor
receptor
egfr
inhibitor
amelior
exagger
proinflammatori
respons
mous
copd
exacerb
model
collect
studi
demonstr
previous
unrecognis
proinflammatori
effect
infect
thu
highlight
key
unforeseen
role
drive
copd
exacerb
sever
authorfund
right
reserv
reus
allow
without
permiss
chronic
obstruct
pulmonari
diseas
copd
inflammatori
airway
disord
punctuat
acut
exacerb
frequent
precipit
rhinovirus
rv
exacerb
major
caus
morbid
mortal
copd
greater
understand
underli
pathophysiolog
mechan
urgent
need
facilit
develop
new
therapi
reduc
impact
debilit
episod
respiratori
mucos
surfac
continu
expos
inhal
pathogen
protect
layer
secret
mucu
rich
mucin
glycoprotein
act
firstlin
defens
infect
alter
mucu
secret
includ
enhanc
major
airway
mucin
cardin
featur
inflammatori
airway
copd
complex
interact
mucin
pathogen
perturb
mucin
express
occur
copd
affect
infect
suscept
subsequ
exacerb
pathogenesi
poorli
understood
known
whether
inhibit
mucu
product
would
benefici
harm
context
anim
studi
reveal
critic
role
antivir
antibacteri
hostdefens
suggest
use
antisecretori
therapi
may
compromis
protect
role
mucin
exacerb
convers
mucin
level
higher
copd
patient
experi
frequent
exacerb
rais
specul
possibl
function
role
exacerb
pathogenesi
addit
accumul
small
airway
mucuscontain
inflammatori
exud
shown
associ
earli
death
patient
copd
treat
lung
volum
reduct
surgeri
airway
mediat
airway
hyperrespons
overexpress
case
fatal
asthma
suggest
mucin
could
marker
caus
advers
outcom
studi
would
support
oppos
view
target
suppress
mucin
exacerb
might
provid
desir
improv
outcom
use
human
studi
combin
function
experi
mous
model
identifi
central
unforeseen
role
amplifi
virusinduc
airway
inflamm
drive
subsequ
exacerb
sever
copd
identifi
mechan
augment
virusinduc
inflamm
releas
extracellular
adenosin
triphosph
atp
show
therapeut
suppress
virusinduc
releas
use
epiderm
growth
factor
receptor
egfr
inhibitor
amelior
exagger
proinflammatori
respons
mous
copd
exacerb
model
studi
first
implic
key
function
driver
copd
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
exacerb
pathogenesi
indic
select
therapeut
inhibit
mucin
could
lead
improv
clinic
outcom
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
initi
evalu
express
major
mucin
glycoprotein
sputum
sampl
taken
copd
patient
virusassoci
naturallyoccur
exacerb
communitybas
cohort
studi
total
exacerb
report
exacerb
associ
posit
viru
detect
pcr
sputum
sampl
rhinoviru
coronaviru
rsv
influenza
previous
report
virusposit
exacerb
sampl
use
analys
see
tabl
clinic
characterist
subject
report
exacerb
signific
increas
baselin
observ
sputum
supernat
protein
concentr
exacerb
present
week
exacerb
signific
increas
observ
protein
exacerb
peak
concentr
ie
maxim
concentr
detect
exacerb
protein
increas
compar
baselin
signific
increas
observ
frequent
exacerb
patient
histori
exacerb
preced
year
increas
sputum
concentr
exacerb
present
week
exacerb
compar
infrequ
exacerb
exacerb
preced
year
signific
differ
observ
fig
given
elisabas
quantif
sputum
mucin
may
influenc
proteas
present
sampl
type
confirm
observ
use
quantit
pcr
measur
mucin
express
rna
extract
sputum
cell
subject
keep
find
mucin
protein
also
observ
sputum
mrna
significantli
increas
exacerb
onset
increas
observ
mrna
fig
provid
addit
evid
major
induc
mucin
naturallyoccur
copd
exacerb
next
utilis
previou
human
rv
challeng
studi
accur
defin
tempor
dynam
mucin
express
rvinduc
copd
exacerb
supplementari
clinic
characterist
subject
shown
tabl
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
signific
increas
sputum
baselin
observ
rvinfect
copd
subject
day
postinfect
increas
observ
healthi
control
subject
increas
patient
copd
versu
healthi
control
day
postinfect
signific
chang
baselin
time
point
patient
copd
healthi
control
differ
observ
two
group
infect
supplementari
peak
concentr
increas
patient
copd
compar
baselin
signific
chang
observ
healthi
individu
peak
concentr
higher
copd
compar
healthi
subject
peak
concentr
increas
group
volunt
compar
baselin
signific
differ
observ
two
group
supplementari
characteris
express
mucin
exacerb
note
induct
occur
day
timepoint
preced
peak
airway
inflamm
occur
day
postinfect
next
sought
assess
relationship
respons
inflammatori
respons
infect
human
experiment
challeng
model
observ
highli
signific
posit
correl
sputum
cellular
airway
inflamm
total
cell
count
neutrophil
count
concentr
solubl
mediat
inflamm
includ
gmcsf
tnf
sinc
viru
replic
act
driver
airway
inflamm
also
examin
relationship
sputum
mucin
viru
load
found
posit
correl
sputum
sputum
viru
load
previous
report
rhinoviru
infect
induc
secondari
bacteri
infect
copd
neutrophil
elastas
cleav
antimicrobi
peptid
amp
secretori
leucocyt
proteinas
inhibitor
slpi
elafin
promot
bacteri
growth
found
sputum
correl
posit
sputum
neutrophil
elastas
concentr
infect
neg
chang
baselin
sputum
slpi
elafin
concentr
infect
consist
greater
level
infect
associ
greater
induct
neutrophil
elastas
consequ
increas
degrad
amp
copd
patient
posit
bacteri
cultur
rv
infect
also
higher
concentr
sputum
infect
sputum
concentr
correl
bacteri
load
determin
qpcr
confirm
latter
find
observ
rhinoviru
challeng
model
perform
similar
analys
natur
occur
copd
exacerb
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
found
sputum
concentr
virusinduc
exacerb
also
correl
bacteri
load
week
sampl
exacerb
peak
secondari
bacteri
infect
occur
around
week
viru
infect
supplementari
although
induc
infect
time
point
assess
similar
analys
carri
howev
contrast
significantli
correl
inflammatori
marker
except
gmcsf
supplementari
similarli
signific
correl
viru
load
supplementari
chang
baselin
antimicrobi
peptid
concentr
supplementari
fig
bacteri
load
experiment
supplementari
naturallyoccur
supplementari
copd
exacerb
proinflammatori
cytokin
cellular
airway
inflamm
believ
contribut
durat
sever
rvinduc
asthma
exacerb
secondari
bacteri
infect
also
associ
greater
exacerb
sever
rvinduc
copd
exacerb
observ
associ
concentr
airway
inflamm
viru
load
secondari
bacteri
infect
next
determin
whether
airway
mucin
exacerb
relat
clinic
outcom
exacerb
observ
sputum
concentr
correl
upper
lower
respiratori
tract
symptom
score
signific
correl
observ
supplementari
sinc
chronic
mucu
hypersecret
associ
long
term
fev
declin
also
hypothes
amplifi
induct
rv
infect
would
relat
acut
lung
function
chang
copd
exacerb
experiment
rvinduc
copd
exacerb
sputum
concentr
correl
neg
maxim
fall
baselin
peak
expiratori
flow
exacerb
fig
correl
observ
supplementari
confirm
find
addit
measur
altern
sampl
type
bronchoalveolar
lavag
bal
subject
experiment
infect
studi
also
underw
bronchoscopi
baselin
day
rv
infect
bal
protein
similarli
increas
copd
subject
versu
healthi
nonsmok
differ
observ
supplementari
fig
combin
observ
confirm
major
induc
mucin
human
virusinduc
copd
exacerb
concentr
correl
inflamm
viru
load
secondari
bacteri
infect
clinic
measur
exacerb
sever
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
next
sought
understand
function
import
rv
infect
use
mous
model
caus
effect
relationship
readili
assess
mice
genetarget
delet
attenu
cellular
airway
inflamm
bal
total
cell
count
neutrophil
number
reduc
concentr
neutrophil
chemokin
fig
follow
rv
infect
compar
wildtyp
control
bal
concentr
proinflammatori
cytokin
tnf
also
reduc
rvinfect
compar
wildtyp
control
fig
proinflammatori
effect
mediat
via
interfer
antivir
immun
respons
viru
control
wild
type
control
similar
level
protein
bal
differ
lung
viru
load
supplementari
fig
data
indic
function
relat
airway
inflammatori
respons
rv
infect
confirm
function
role
rvinduc
inflamm
exacerb
sever
evalu
vivo
effect
exogen
glycoprotein
mous
model
rv
infect
exogen
administr
alon
effect
bal
inflammatori
cell
number
proinflammatori
chemokin
cytokin
concentr
administr
enhanc
rvinduc
airway
inflamm
includ
increas
total
cell
neutrophil
number
fig
increas
bal
concentr
proinflammatori
chemokin
cytokin
tnf
convers
administr
protein
control
polym
solut
agarosedextran
concentr
effect
inflamm
either
alon
administ
combin
rv
infect
mice
supplementari
fig
consist
hypothesi
drive
neutrophil
elastasemedi
cleavag
amp
subsequ
increas
bacteri
load
also
observ
exogen
increas
rvinduct
neutrophil
elastas
suppress
rvinduct
slpi
augment
lung
bacteri
load
viru
infect
similar
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
observ
knockout
mice
exogen
also
effect
induct
lung
viru
load
rvinfect
mice
supplementari
next
sought
understand
amplifi
inflamm
rv
infect
given
prior
observ
delet
antiinflammatori
augment
exogen
protein
mice
broad
proinflammatori
effect
reason
mucin
could
mediat
effect
via
danger
signal
promot
inflammatori
mediat
releas
cell
recruit
previou
studi
demonstr
supernat
mucopurul
materi
subject
cystic
fibrosi
induc
epitheli
releas
extracellular
adenosin
triphosph
atp
wellrecognis
promot
inflamm
also
virusinduc
therefor
hypothesis
exert
proinflammatori
effect
rv
infect
via
induct
extracellular
atp
examin
effect
atp
neutralis
use
atphydrolys
enzym
apyras
exogen
rvinfect
mice
fig
exogen
protein
administr
augment
bal
concentr
atp
rvinfect
mice
effect
abrog
instil
apyras
fig
apyras
administr
also
suppress
exogen
increas
airway
inflamm
rv
infect
includ
bal
total
cell
neutrophil
fig
inflammatori
chemokin
fig
proinflammatori
cytokin
tnf
fig
apyras
also
prevent
exogen
increas
neutrophil
elastas
revers
suppress
slpi
suppress
increas
bacteri
load
rvinfect
mice
fig
apyrasemedi
revers
proinflammatori
effect
occur
via
interfer
antivir
immun
respons
viru
control
also
observ
effect
apyras
rvinduct
supplementari
c
lung
viru
load
supplementari
data
confirm
exert
proinflammatori
effect
rv
infect
induct
releas
extracellular
atp
confirm
function
import
rvinduc
airway
inflamm
next
hypothesis
inhibit
rvinduct
glycoprotein
would
benefici
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
effect
rvinduc
copd
exacerb
rhinovirus
induc
express
egfr
signal
therefor
assess
effect
egfr
inhibit
mous
model
elastaseinduc
emphysema
combin
rvinfect
mani
featur
human
copd
exacerb
includ
mucu
hypersecret
recapitul
administr
egfr
inhibitor
prior
rv
infect
elastas
treat
mice
suppress
rvinduct
lung
mrna
bal
protein
suppress
airway
epitheli
cell
mucu
stain
lung
section
fig
control
group
shown
supplementari
fig
effect
bal
protein
concentr
supplementari
b
administr
elastasetr
mice
also
suppress
rvinduct
bal
cellular
airway
inflamm
well
chemokin
proinflammatori
cytokin
tnf
gmcsf
neutrophil
elastas
treatment
elastasetr
rvinfect
mice
also
enhanc
bal
slpi
level
reduc
pulmonari
bacteri
load
final
elastas
rvinfect
mice
reduc
ahr
methacholin
challeng
compar
elastas
vehicl
treat
rv
infect
control
antiinflammatori
effect
mediat
via
interfer
antivir
immun
respons
viru
control
also
observ
effect
rvinduct
supplementari
lung
viru
load
supplementari
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mechan
underli
virusinduc
exacerb
copd
factor
drive
inflamm
clinic
sever
episod
poorli
understood
provid
insight
role
major
airway
mucin
glycoprotein
play
biolog
episod
use
combin
human
mous
model
rhinoviru
infect
copd
demonstr
novel
central
role
virusinduc
drive
copd
exacerb
sever
amplif
airway
inflamm
find
open
new
opportun
target
therapeut
indic
mechan
augment
rvinduc
inflamm
via
releas
extracellular
atp
show
select
induc
virusinduc
copd
exacerb
increas
compar
virusinfect
healthi
subject
contrast
induc
baselin
differ
copd
control
subject
timepoint
indic
major
induc
mucin
exacerb
also
found
posit
correl
rang
inflammatori
marker
sinc
airway
inflamm
enhanc
copd
exacerb
believ
contribut
durat
sever
rv
induc
ill
also
determin
relationship
exacerb
sever
find
posit
correl
viru
load
symptom
score
acut
lung
function
declin
one
major
glycoprotein
compon
airway
mucu
therefor
unsurpris
express
viru
infect
correl
lower
respiratori
symptom
score
compris
assess
sputum
product
correl
pef
declin
explain
fact
greater
mucu
product
like
contribut
directli
airway
obstruct
exacerb
find
acut
human
infect
model
keep
clinic
studi
report
associ
symptomdefin
chronic
mucu
hypersecret
phenotyp
airflow
limit
fev
declin
anim
studi
show
genet
delet
reduc
mucu
occlus
improv
lung
function
model
allerg
airway
inflamm
previous
report
experiment
rv
infect
patient
copd
associ
increas
frequenc
secondari
bacteri
infect
compar
healthi
subject
via
mechan
virusinduc
neutrophil
elastasemedi
cleavag
antimicrobi
peptid
slpi
elafin
posit
correl
sputum
neutrophil
number
neutrophil
elastas
concentr
secondari
bacteri
infect
neg
correl
slpi
elafin
level
observ
current
studi
suggest
increas
could
one
mechan
contribut
enhanc
neutrophil
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
exogen
also
enhanc
rhinovirusinduct
neutrophil
elastas
suppress
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
slpi
product
increas
pulmonari
bacteri
load
confirm
role
ehr
et
al
evalu
respons
influenza
infect
transgen
overexpress
mous
strain
show
reduc
viral
titr
attenu
neutrophil
inflamm
model
contrast
find
use
exogen
administr
effect
viru
load
enhanc
virusinduc
inflamm
transgen
strain
employ
ehr
et
al
associ
increas
airway
level
level
augment
greatli
exce
increas
observ
human
analys
increas
observ
stabl
state
level
copd
versu
healthi
subject
increas
observ
baselin
exacerb
concentr
exogen
protein
administ
anim
experi
fold
higher
baselin
protein
concentr
measur
mous
airway
therefor
like
physiolog
relev
human
exacerb
effect
reduc
viru
load
much
higher
level
gener
transgen
strain
report
ehr
et
al
may
virusspecif
author
report
bind
influenza
viru
receptor
sialic
acid
transgen
anim
consist
mechan
influenza
protect
vivo
impair
effici
bind
viru
receptor
bronchial
epithelium
lead
reduct
viru
load
consequ
lesser
inflamm
import
note
use
nonhuman
purifi
mucin
protein
solut
experi
fulli
recapitul
complex
biophys
properti
mucin
glycoprotein
contain
within
endogen
airway
mucu
confirm
mucin
prepar
use
free
endotoxin
dna
exclud
mucinbound
protein
present
solut
may
contribut
observ
effect
futur
valid
find
use
administr
human
mous
similar
mous
model
warrant
although
extract
purif
mucin
sourc
technic
challeng
feasibl
current
studi
identifi
mechan
amplif
rhinovirusinduc
airway
inflamm
releas
atp
danger
signal
releas
infect
contribut
nucleotid
receptordepend
inflammatori
respons
mechan
suggest
previou
studi
indic
administr
steril
supernat
mucopurul
materi
subject
cystic
fibrosi
induc
atp
releas
human
bronchial
epitheli
cell
vitro
role
atp
potenti
driver
airway
inflamm
stabl
asthma
copd
well
recognis
find
model
infect
neutralis
pulmonari
atp
level
abrog
enhanc
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
inflamm
secondari
bacteri
infect
identifi
novel
mechan
rhinovirusinduc
mucin
product
enhanc
copd
exacerb
sever
addit
observ
directli
augment
rhinovirusinduc
airway
inflamm
number
previou
studi
also
demonstr
inflammatori
mediat
neutrophil
elastas
directli
induc
express
lung
epithelium
therefor
specul
mucininduc
airway
inflamm
might
trigger
product
lead
viciou
cycl
contribut
enhanc
airway
inflamm
mucu
hypersecret
drive
exacerb
sever
copd
thu
hypothesis
earli
target
rhinoviru
infect
might
benefici
interrupt
cycl
evalu
effect
upstream
inhibit
rhinovirusinduct
use
egfr
inhibitor
copd
exacerb
mous
model
suppress
rhinovirusinduc
level
accompani
reduc
airway
inflamm
proinflammatori
cytokin
chemokin
neutrophil
elastas
ahr
well
enhanc
slpi
product
reduc
bacteri
load
rhinovirusinfect
elastasetr
mice
importantli
impact
antivir
respons
viru
control
reassuringli
indic
therapi
aim
inhibit
product
would
expect
advers
affect
antivir
hostdef
jing
et
al
recent
report
copd
airway
epitheli
cell
cultur
administr
egfr
inhibitor
effect
rvinduct
conclud
egfr
play
role
promot
virusinduc
mucin
express
copd
howev
studi
author
examin
mucin
express
sole
late
timepoint
day
post
rv
infect
evalu
effect
treatment
mucin
express
earlier
timepoint
subsequ
effect
product
inflammatori
mediat
data
human
challeng
model
indic
peak
rv
induct
occur
much
earlier
timepoint
day
previou
studi
shown
egfr
inhibit
attenu
earli
induct
rvstimul
airway
epitheli
cell
cultur
data
mous
model
copdlik
diseas
support
assert
earli
product
respons
rv
infect
occur
egfr
thu
amen
therapeut
inhibit
previou
studi
use
inhal
egfr
inhibitor
stabl
copd
report
effect
egfr
inhibit
relat
greater
decreas
epitheli
mucin
store
higher
dose
drug
poorli
toler
system
egfr
antagonist
commonli
use
lung
adenocarcinoma
therapi
data
mice
provid
justif
human
studi
evalu
role
repurpos
agent
use
copd
exacerb
inhibit
product
could
theoret
suppress
airway
inflamm
reduc
secondari
bacteri
infect
diminish
exacerb
sever
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mucin
quantifi
studi
use
elisabas
assay
histor
collect
sputum
sampl
specif
within
separ
sputum
plug
aliquot
sampl
type
avail
us
sputum
plug
sever
asthmat
previous
shown
contain
constitu
like
contain
surfac
goblet
cell
deriv
mucin
may
contribut
differ
observ
induct
two
mucin
studi
howev
also
observ
increas
rvinduc
altern
sampl
type
bal
copd
subject
versu
healthi
subject
support
find
sputum
also
evid
suggest
proteas
within
sputum
sampl
interfer
immunodetect
mucin
studi
attempt
address
use
treatment
proteas
inhibitor
shortli
sputum
collect
previous
report
use
sampl
studi
neutrophil
elastas
increas
copd
subject
compar
healthi
subject
follow
viru
challeng
given
observ
greater
induct
protein
copd
subject
compar
healthi
subject
despit
increas
level
proteas
suggest
actual
differ
two
group
could
even
substanti
observ
studi
addit
find
sputum
mrna
express
increas
naturallyoccur
exacerb
mirror
observ
protein
level
provid
addit
confirmatori
approach
would
subject
potenti
confound
studi
use
altern
semiquantit
antibodyindepend
techniqu
unclear
whether
approach
would
suffici
sensit
detect
subtl
chang
mucin
express
infect
primari
aim
human
compon
studi
studi
mucin
level
chang
virusinduc
exacerb
studi
uniqu
sequenti
sampl
individu
patient
exacerb
consist
method
use
measur
mucin
subject
conclus
show
major
induc
mucin
viru
infect
copd
virusinduc
play
central
role
drive
airway
inflamm
exacerb
sever
copd
futur
develop
repurpos
therapi
specif
target
compon
mucu
could
lead
improv
clinic
outcom
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sampl
analys
subject
recruit
two
experiment
rhinoviru
infect
studi
publish
previous
sampl
two
group
includ
analysi
copd
subject
gold
stage
ii
use
regular
inhal
therapi
healthi
nonsmok
subject
gave
inform
written
consent
protocol
approv
subject
initi
visit
baselin
clinic
stabl
clinic
assess
pef
clinic
sampl
collect
includ
spontan
induc
sputum
taken
previous
describ
subject
report
studi
team
develop
symptom
upper
respiratori
tract
infect
increas
symptom
dyspnoea
cough
sputum
volum
purul
exacerb
defin
use
east
london
cohort
criteria
subject
seen
within
hour
onset
symptom
collect
sampl
repeat
visit
schedul
two
six
week
initi
exacerb
visit
clinic
assess
lung
function
induc
sputum
repeat
timepoint
virus
detect
sputum
pcr
describ
previous
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
femal
mice
age
week
purchas
charl
river
laboratori
background
use
wildtyp
anim
studi
gener
background
univers
colorado
previous
describ
evalu
egfr
inhibitor
copd
exacerb
model
previous
report
mice
treat
intranas
light
isofluran
anaesthesia
unit
porcin
pancreat
elastas
merck
uk
induc
copdlik
chang
ten
day
follow
elastas
administr
previous
describ
mice
treat
intraperiton
egfr
inhibitor
hour
prior
intranas
infect
x
tcid
uvinactiv
control
cytokin
protein
level
mous
bal
human
sputum
supernat
cell
supernat
vitro
experi
assay
use
commerci
duoset
enzymelink
immunosorb
assay
kit
r
system
abingdon
uk
mesoscal
discoveri
msd
platform
maryland
usa
use
measur
inflammatori
mediat
tnf
gmcsf
sputum
supernat
accord
manufactur
instruct
publish
previous
protein
level
human
secretori
leucocyt
proteinas
inhibitor
slpi
elafin
neutrophil
elastas
mous
bal
protein
assay
use
commerci
elisa
assay
kit
previous
describ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
protein
previous
store
human
sputum
plug
humanmous
bal
measur
adhes
well
plate
allow
sampl
evapor
c
overnight
use
inhous
assay
previous
describ
measur
detect
antibodi
use
biotinyl
thermoscientif
uk
ngml
assay
detect
antibodi
mous
clone
previous
describ
bound
antibodi
detect
peroxidaseconjug
goat
antimous
igg
sigmaaldrich
uk
mucin
quantifi
follow
standard
purifi
porcin
previous
describ
recombin
protein
caltag
medsystem
uk
measur
atp
level
mous
bal
supernat
atplit
assay
perkin
elmer
use
accord
manufactur
instruct
cell
lysi
step
omit
previous
describ
human
studi
total
rna
extract
sputum
cell
rneasi
kit
qiagen
use
cdna
synthesi
omniscript
rt
kit
mous
model
total
rna
extract
right
upper
lobe
mous
lung
place
rna
later
prior
rna
extract
cdna
synthesi
quantit
pcr
qpcr
carri
use
previous
describ
specif
primer
probe
human
mous
rhinoviru
rna
copi
number
normal
rrna
dna
extract
human
sputum
mous
lung
perform
use
fastdna
spin
kit
soil
mp
biomed
usa
follow
manufactur
instruct
beadbeat
perform
two
cycl
second
rpm
precelli
bertin
technolog
franc
bacteri
load
measur
use
qpcr
previous
describ
data
human
copd
studi
analys
use
wilcoxon
matchedpair
sign
rank
test
mannwitney
u
test
correl
dataset
examin
use
spearman
rank
correl
coeffici
mous
experi
anim
studi
group
size
mice
data
shown
repres
least
independ
experi
data
analys
use
one
twoway
anova
signific
differ
group
assess
bonferroni
multipl
comparison
test
statist
perform
use
graphpad
prism
softwar
differ
consid
signific
p
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
c
individu
datapoint
shown
analys
wilcoxon
matchedpair
sign
rank
test
baselin
vs
peak
mann
witney
u
test
comparison
peak
valu
copd
healthi
subject
p
p
h
left
panel
data
analys
mann
witney
u
test
p
panel
correl
analysi
use
nonparametr
spearman
correl
perform
healthi
volunt
individu
copd
pool
singl
group
h
right
panel
qpcr
measur
patient
due
lack
sampl
avail
data
shown
measur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mice
treat
intranas
elastas
pb
control
addit
treat
intraperiton
egfr
inhibitor
prior
challeng
rhinoviru
rv
uvinactiv
uv
day
rv
challeng
lung
formalinfix
paraffinembed
stain
period
acidschiff
pa
repres
imag
shown
mice
treat
pb
uv
vehicl
b
elastas
uv
vehicl
c
elastas
rv
vehicl
elastas
rv
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
previou
studi
reveal
properti
commerci
avail
mucin
differ
key
properti
nativ
mucin
system
eg
lack
abil
reduc
friction
lead
cytotox
effect
differ
attribut
harsh
condit
commerci
purif
process
consequ
purif
porcin
gastric
perform
manual
fresh
pig
stomach
optim
origin
purif
protocol
celli
etal
describ
detail
previous
brief
crude
mucu
obtain
gentli
scrape
pig
stomach
rins
tap
water
mucu
dilut
mm
sodium
phosphat
buffer
ph
supplement
mm
nacl
homogen
stir
overnight
cellular
debri
remov
via
sever
centrifug
step
x
g
min
x
g
min
final
ultracentrifug
step
x
g
h
afterward
supernat
separ
chromatograph
sizeexclus
chromatographi
purifi
system
ge
healthcar
equip
column
pack
sepharos
fraction
contain
mucin
glycoprotein
identifi
via
pa
period
acidschiff
base
stain
pool
subsequ
dialysi
step
ultrapur
water
via
crossflow
filtrat
mucinsolut
concentr
lyophil
store
lyophil
bovin
salivari
mucin
powder
purchas
merck
darmstadt
germani
dissolv
mm
sodium
phosphat
buffer
ph
supplement
nacl
concentr
mg
ml
solut
rotat
rotat
incub
h
purif
salivari
mucin
conduct
accord
protocol
use
purifi
gastric
mucin
describ
sinc
gastric
mucosa
also
contain
dna
enzymat
remov
potenti
mucinassoci
dna
perform
prevent
dnarel
inflamm
reaction
follow
step
carri
steril
hood
lyophil
mucin
purifi
porcin
gastric
mucosa
treat
uvlight
ice
hour
subsequ
dissolv
mm
trishcl
buffer
steril
filter
ph
supplement
mm
mgcl
concentr
mgml
kept
ice
dnase
bovin
pancrea
sigma
aldrich
st
loui
mo
usa
dissolv
buffer
concentr
mgml
dnase
solut
ad
per
milligram
dissolv
mucin
afterward
mucindnas
solut
incub
hour
tube
shaker
rpm
treat
mucin
chromatograph
separ
enzym
residu
dna
fragment
via
size
exclus
chromatographi
subsequ
desalt
mean
crossflow
filtrat
lyophil
see
purif
porcin
gastric
mucin
section
dnase
treat
mucin
store
lyophil
form
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
visual
mucinassoci
dna
success
remov
dna
verifi
electrophoret
separ
mucin
sampl
subsequ
visual
associ
dna
molecul
via
dnabind
dye
sybr
green
sigma
aldrich
st
loui
mo
usa
therefor
mucin
sampl
mix
laemmli
buffer
load
polyacrylamid
gel
miniprotean
tgx
gel
biorad
hercul
ca
usa
separ
v
min
v
dye
front
reach
end
gel
gel
stain
use
sybr
green
afterward
dilut
tbe
buffer
room
temperatur
gentl
shake
min
dna
stain
visual
gel
doc
ez
gel
document
system
biorad
epiillumin
wavelength
nm
fig
addit
confirm
dna
undetect
sampl
protein
use
quantit
picogreen
dsdna
reagent
invitrogen
carlsbad
ca
accord
manufactur
protocol
previous
describ
